

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kindstar Globalgene Technology, Inc.

康聖環球基因技術有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9960)

PROFIT WARNING

This announcement is made by Kindstar Globalgene Technology, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of The Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company wishes to inform the shareholders (the “**Shareholders**”) and potential investors of the Company that, based on the Group’s unaudited consolidated management accounts for the six months ended June 30, 2025 (“**1H2025**”) and other information currently available to the Board, the net loss that may be recorded by the Group for 1H2025 is expected to be within the range of approximately RMB30 million to RMB35 million as compared to the net profit of the Company of approximately RMB10.5 million for the six months ended June 30, 2024 (“**1H2024**”). The expected net losses were mainly due to the fact that:

1. Revenue for 1H2025 decreased by RMB16.4 million, representing a decrease of 3.5% as compared to 1H2024.
2. The amount of loss arising from fair value change on the funds that the Company participated in was approximately RMB10.15 million.
3. During 1H2025, the Company newly provided for the expected credit loss on accounts receivables related to COVID-19 business of approximately RMB8.42 million.
4. The incremental expenses incurred from the acquisition of Guangzhou AnchorDx Medical Co., Ltd. and Guangzhou Kangchengweiye Biotechnology Co., Ltd. (collectively, the “**Acquired Subsidiaries**”), along with the losses of the Acquired Subsidiaries in the 1H2025 amount to approximately RMB16 million in 1H2025.

Excluding the impact of the above factors, the core business of the Group remained stable.

The Company is still in the process of finalizing the interim results of the Group for 1H2025. The information contained in this announcement is only based on the preliminary assessment by the Board according to the unaudited consolidated management accounts of the Group for 1H2025 and the currently available information, which have not been audited or reviewed by the Company’s auditor or the audit committee of the Company, and may be subject to further adjustments and may differ from the figures to be disclosed in the interim results announcement of the Company for 1H2025 (the “**Interim Results Announcement**”). Shareholders and potential investors of the Company should read carefully the Interim Results Announcement, which is expected to be published by the end of August 2025 in accordance with the requirements of the Listing Rules.

Shareholders and potential investors are advised to exercise due caution when dealing in the shares of the Company.

By Order of the Board
Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
HUANG Shiang
Chairman

Hong Kong, August 22, 2025

As of the date of this announcement, the Board comprises Dr. HUANG Shiang, Mr. TU Zanbing and Ms. CHAI Haijie as executive Directors, Mr. HUANG Zuie-Chin, Mr. PENG Wei and Ms. HUANG Lu as non-executive Directors, and Dr. YAO Shanglong, Dr. XIA Xinping and Mr. GU Huaming as independent non-executive Directors.